Insomnia during the COVID-19 pandemic: prevalence and correlates in a multi-ethnic population Singapore.

Insomnia during the COVID-19 pandemic: prevalence and correlates in a multi-ethnic population Singapore.

Publication date: Dec 27, 2024

Globally, the Coronavirus disease 2019 (COVID-19) pandemic had a significant impact on mental health. Sudden lifestyle changes, threatening information received through various sources, fear of infection and other stressors led to sleep disturbances such as insomnia. The current study aimed to assess the prevalence of insomnia and its associated risk factors during the first wave of COVID-19 pandemic among Singapore residents. A cross-sectional study conducted online and in person, from May 2020 to June 2021, recruited Singapore citizens and permanent residents, aged 21 years and above, fluent in English, Chinese or Malay language. Respondents answered an interviewer-administered questionnaire, including Insomnia Severity Index (ISI), Generalised Anxiety Disorder-7 (GAD-7), Physical Health Questionnaire (PHQ-9), stress scale of the Depression, Anxiety and Stress Scales (DASS), chronic conditions checklist and COVID-19 related stressors (exposure to COVID-19, current and future perceived risk of infection). Chi-squared test followed by stepwise logistic regression analysis were conducted to determine factors associated with insomnia. The study recruited 1129 respondents. Prevalence of insomnia was noted to be 7. 4% in the sample. Insomnia was significantly associated with psychological distress- depression (p 

Open Access PDF

Concepts Keywords
Coronavirus Adult
Fluent Aged
June COVID-19
Pandemic COVID-19 pandemic
Sleep Cross-Sectional Studies
Ethnicity
Female
Humans
Insomnia
Male
Mental health
Middle Aged
Pandemics
Prevalence
Psychological distress
Risk Factors
Risk factors
SARS-CoV-2
Singapore
Singapore
Stress, Psychological
Surveys and Questionnaires
Young Adult

Semantics

Type Source Name
disease MESH Insomnia
disease MESH COVID-19 pandemic
disease MESH lifestyle
disease MESH infection
disease MESH Anxiety Disorder
disease MESH Depression
disease MESH Anxiety
disease MESH chronic conditions
disease MESH psychological distress
pathway REACTOME Reproduction
drug DRUGBANK Coenzyme M
disease MESH asthma
pathway KEGG Asthma
disease MESH backache
disease MESH narcolepsy
disease MESH restless leg syndrome
disease MESH parasomnias
disease MESH sequelae
disease MESH Mental Disorders
drug DRUGBANK Indoleacetic acid
disease MESH psychological well being
disease IDO process
disease MESH daytime sleepiness
disease MESH cognitive impairment
disease IDO immunosuppression
disease MESH loneliness
drug DRUGBANK Hydrocortisone
disease IDO production
drug DRUGBANK Melatonin
disease MESH uncertainty
disease MESH comorbidity
disease MESH virus infection
disease MESH suicidal ideation
disease MESH marital status
disease MESH anhedonia
disease MESH hypertension
disease IDO history
disease MESH unemployment
drug DRUGBANK Aspartame
disease MESH tic
disease MESH Migraine
drug DRUGBANK Esomeprazole
drug DRUGBANK Trestolone
disease MESH morbidities
disease MESH lung disease
disease MESH pneumonia
disease MESH death
disease MESH pain threshold
drug DRUGBANK Dopamine
disease MESH restlessness
drug DRUGBANK Norepinephrine
disease MESH inflammation
disease MESH causality
disease MESH long COVID
drug DRUGBANK Nevirapine
drug DRUGBANK Caffeine
drug DRUGBANK Ethanol
disease MESH infectious diseases
drug DRUGBANK Carboxyamidotriazole
disease MESH Insufficient sleep syndrome
disease MESH Noncommunicable Disease
disease MESH Sleep Quality
disease MESH sleep disorder
disease MESH Parkinson’s disease
disease MESH Multiple chronic conditions
drug DRUGBANK Etoperidone
disease MESH low back Pain
disease MESH Stress Psychological

Original Article

(Visited 1 times, 1 visits today)